MEDP in the 13F filings
Medpace HLDGS Inc · CUSIP 58506Q109
- Quarter end
- 30 Sep 2025
- the date the book describes
- Filed
- 17 Nov 2025
- latest of these filings; the earliest 31 Oct 2025
- Managers listing it
- 17
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q2 2025 and Q3 2025; 11 listed it in both
- Shares listed
- 3,678,420
- combined, among listed positions
- Reported value
- $1.9bn
- combined, at the quarter end
Among the 95 comparable managers: 9 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing MEDP in Q3 2025
17 of 17 holders
Largest increases and reductions, by shares
Increases
- AQR Capital Management LLCexisting position · 1,025,410 shares now+404,226
- D. E. Shaw & Co.existing position · 600,140 shares now+256,577
- Baillie Gifford & Coexisting position · 584,796 shares now+62,503
- Bridgewater Associates LPnew position · 33,230 shares now+33,230
- Caxton Associates LLPnew position · 20,804 shares now+20,804
Reductions
- Two Sigma Advisers LPexisting position · 88,200 shares now-190,200
- Renaissance Technologies LLCexisting position · 493,588 shares now-184,500
- Two Sigma Investments LPexisting position · 85,369 shares now-181,381
- Voloridge Investment Management LLCexisting position · 190,994 shares now-39,848
- Quantbot Technologies LPexisting position · 16,212 shares now-17,963
New positions and exits
New (3)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2017 | 2 | $21m | n.a. | n.a. |
| Q2 2017 | 1 | $14m | n.a. | n.a. |
| Q3 2017 | 1 | $19m | n.a. | n.a. |
| Q4 2017 | 1 | $23m | n.a. | n.a. |
| Q1 2018 | 3 | $37m | n.a. | n.a. |
| Q2 2018 | 4 | $59m | n.a. | n.a. |
| Q3 2018 | 14 | $247m | n.a. | n.a. |
| Q4 2018 | 6 | $119m | n.a. | n.a. |
| Q1 2019 | 4 | $100m | n.a. | n.a. |
| Q2 2019 | 4 | $117m | n.a. | n.a. |
| Q3 2019 | 6 | $140m | n.a. | n.a. |
| Q4 2019 | 5 | $122m | n.a. | n.a. |
| Q1 2020 | 7 | $144m | n.a. | n.a. |
| Q2 2020 | 8 | $173m | n.a. | n.a. |
| Q3 2020 | 12 | $218m | n.a. | n.a. |
| Q4 2020 | 8 | $187m | n.a. | n.a. |
| Q1 2021 | 9 | $153m | n.a. | n.a. |
| Q2 2021 | 8 | $156m | n.a. | n.a. |
| Q3 2021 | 11 | $413m | n.a. | n.a. |
| Q4 2021 | 12 | $668m | n.a. | n.a. |
| Q1 2022 | 6 | $107m | n.a. | n.a. |
| Q2 2022 | 5 | $97m | n.a. | n.a. |
| Q3 2022 | 3 | $59m | n.a. | n.a. |
| Q4 2022 | 10 | $269m | n.a. | n.a. |
| Q1 2023 | 14 | $275m | n.a. | n.a. |
| Q2 2023 | 17 | $468m | n.a. | n.a. |
| Q3 2023 | 15 | $378m | n.a. | n.a. |
| Q4 2023 | 14 | $501m | 8 | 7 |
| Q1 2024 | 17 | $1.2bn | 9 | 8 |
| Q2 2024 | 18 | $1.3bn | 9 | 9 |
| Q3 2024 | 15 | $918m | 9 | 6 |
| Q4 2024 | 15 | $1.2bn | 9 | 6 |
| Q1 2025 | 12 | $986m | 11 | 1 |
| Q2 2025 | 14 | $1.2bn | 12 | 3 |
| Q3 2025 | 17 | $1.9bn | 9 | 8 |
| Q4 2025 | 14 | $2.1bn | 14 | 21 |
| Q1 2026 | 12 | $1.8bn | 12 | 21 |
| Q2 2026 | 9 | $2.7bn | 8 | 21 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MEDP and LLY →MEDP and JNJ →MEDP and VRTX →Choose a stock to compare with MEDP →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MEDP, latest filings →Back to the 13F Explorer →